文献速递病毒性肝炎

PRO-C3与CPa9-HNE与慢性丙型肝炎患者肝脏相关结局相关

Serum Markers of Fibroinflammatory Activity PRO-C3 and CPa9-HNE Are Associated with Liver-Related Outcomes in Patients with Chronic Hepatitis C.
PubMed 文献 · J Infect Dis · 2026-01-01

基于HALT-C试验339例晚期慢性丙型肝炎患者基线血清,评估纤维炎症生物标志物PRO-C3与CPa9-HNE与肝脏相关临床结局的关联。基线PRO-C3高者肝脏相关结局风险增加4倍(95%CI 1.91-8.30),且高纤维生成伴低中性粒细胞活性表型风险最高。

要点

  • 基线PRO-C3升高与慢性丙型肝炎肝脏相关结局风险增加4倍相关。
  • 高PRO-C3且低CPa9-HNE的纤维炎症表型肝脏相关结局风险最高。
  • PRO-C3与CPa9-HNE联合分组或可用于纤维炎症疾病表型分类。

核心结论

  • 在HALT-C亚组慢性丙型肝炎患者中,PRO-C3与肝脏相关结局风险相关。
  • 基于PRO-C3和CPa9-HNE的纤维炎症表型分组可能适用于其他慢性肝病,但需适当验证。

研究设计与样本

  • 研究纳入HALT-C队列中339例晚期慢性丙型肝炎患者的基线血清样本。
  • 检测纤维生成标志物nordicPRO-C3™和中性粒细胞活性标志物nordicCPa9-HNE™,评估肝脏相关临床结局。

主要发现

  • 基线PRO-C3高水平者较低水平者肝脏相关结局风险增加4倍(95%CI 1.91-8.30)。
  • 按PRO-C3和CPa9-HNE高低联合分组,高纤维生成且低中性粒细胞活性表型肝脏相关结局风险最高。

关键数值与推荐

  • 基线PRO-C3高水平与低水平相比,肝脏相关结局风险比(HR)为4倍(95%CI 1.91-8.30)。

临床怎么用

  • 基线PRO-C3与CPa9-HNE联合检测可用于识别慢性丙型肝炎中肝脏相关结局高风险患者。
  • 基于上述标志物的纤维炎症表型分类或可扩展至其他慢性肝病,但需外部验证。

局限性

  • 研究基于HALT-C试验的339例晚期慢性丙型肝炎患者亚组,样本量有限。
  • 结论需在其他慢性肝病人群中适当验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis C (CHC) infection remains a global health burden, contributing to the risk of long-term complications such as progressive fibrosis, cirrhosis, and hepatocellular carcinoma, particularly in undiagnosed or untreated individuals. Novel biomarkers for the assessment of disease progression and prognosis are required for fibroinflammatory chronic liver disease. Our study population from the Hepatitis C Antiviral Long Term Treatment Against Cirrhosis (HALT-C) trial was used to investigate the association of neoepitope fibroinflammatory biomarkers with clinical outcomes in patients with CHC infection. METHODS: Baseline serum samples from 339 patients with advanced CHC from the HALT-C cohort were included and assessed for liver-related clinical outcomes. We assessed the fibrogenesis marker nordicPRO-C3™ and the neutrophil activity marker nordicCPa9-HNE™. RESULTS: The active fibrogenesis marker PRO-C3 was associated with disease progression and liver-related outcomes in patients with CHC, with a 4-fold increased hazard (95% CI: 1.91-8.30) of liver-related outcomes in patients with high compared with low PRO-C3 levels at baseline. Grouping patients with a combination of high or low active fibrogenesis, PRO-C3, and high and low neutrophil activity, CPa9-HNE, revealed that the patient endotype with high fibrogenesis and low neutrophil activity had the highest risk of developing liver-related outcomes in patients with CHC. CONCLUSIONS: PRO-C3 was associated with the risk of liver-related outcomes in patients with CHC infection in our HALT-C subpopulation. Grouping patients based on neoepitope biomarkers reflecting active fibrogenesis and neutrophil activity could provide fibroinflammatory disease endotype classification that may be applicable to other chronic liver diseases with appropriate validation.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Skovgaard ET, Wiggers T, Karsdal M, et al. Serum Markers of Fibroinflammatory Activity PRO-C3 and CPa9-HNE Are Associated with Liver-Related Outcomes in Patients with Chronic Hepatitis C. J Infect Dis. 2026. PMID: 41169194. doi:10.1093/infdis/jiaf552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。